

Global Cancer Immunotherapy Drug Market Growth 2026-2032

<https://marketpublishers.com/r/G3D794ED5B75EN.html>

Date: April 2026

Pages: 115

Price: US\$ 3,660.00 (Single User License)

ID: G3D794ED5B75EN

Abstracts

The global Cancer Immunotherapy Drug market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Cancer Immunotherapy Drugs are medications used in the treatment of cancer. These drugs harness the body's immune system to target and destroy cancer cells. Immunotherapy drugs are designed to boost the body's natural defenses against cancer and are used in various forms, including immune checkpoint inhibitors and CAR-T cell therapies.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the "Cancer Immunotherapy Drug Industry Forecast" looks at past sales and reviews total world Cancer Immunotherapy Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Cancer Immunotherapy Drug sales for 2026 through 2032. With Cancer Immunotherapy Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cancer Immunotherapy Drug industry.

This Insight Report provides a comprehensive analysis of the global Cancer Immunotherapy Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Immunotherapy Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cancer Immunotherapy Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Immunotherapy Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Immunotherapy Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Immunotherapy Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

PD-1 Inhibitor

PDL-1 Inhibitor

T-Cell Stimulant

CTLA Antibody

Segmentation by Application:

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Autolus Therapeutics plc

BeiGene

bluebird bio, Inc.

Bristol-Myers Squibb

Celgene Corporation

AstraZeneca plc

Gilead Sciences, Inc.

Incyte Corporation

Jiangsu Hengrui Medicine

Juno Pharmaceuticals Pty Ltd.

Medimmune, LLC

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Roche Holding AG

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cancer Immunotherapy Drug market?

What factors are driving Cancer Immunotherapy Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cancer Immunotherapy Drug market opportunities vary by end market size?

How does Cancer Immunotherapy Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Cancer Immunotherapy Drug Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Cancer Immunotherapy Drug by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Cancer Immunotherapy Drug by Country/Region, 2021, 2025 & 2032
- 2.2 Cancer Immunotherapy Drug Segment by Type
 - 2.2.1 PD-1 Inhibitor
 - 2.2.2 PDL-1 Inhibitor
 - 2.2.3 T-Cell Stimulant
 - 2.2.4 CTLA Antibody
 - 2.2.5 Cancer Immunotherapy Drug Sales by Type
 - 2.2.5.1 Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Cancer Immunotherapy Drug Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Cancer Immunotherapy Drug Sale Price by Type (2021-2026)
- 2.3 Cancer Immunotherapy Drug Segment by Application
 - 2.3.1 Hospital
 - 2.3.2 Clinic
 - 2.3.3 Others
 - 2.3.4 Cancer Immunotherapy Drug Sales by Application
 - 2.3.4.1 Global Cancer Immunotherapy Drug Sale Market Share by Application (2021-2026)

2.3.4.2 Global Cancer Immunotherapy Drug Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Cancer Immunotherapy Drug Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Cancer Immunotherapy Drug Breakdown Data by Company

3.1.1 Global Cancer Immunotherapy Drug Annual Sales by Company (2021-2026)

3.1.2 Global Cancer Immunotherapy Drug Sales Market Share by Company (2021-2026)

3.2 Global Cancer Immunotherapy Drug Annual Revenue by Company (2021-2026)

3.2.1 Global Cancer Immunotherapy Drug Revenue by Company (2021-2026)

3.2.2 Global Cancer Immunotherapy Drug Revenue Market Share by Company (2021-2026)

3.3 Global Cancer Immunotherapy Drug Sale Price by Company

3.4 Key Manufacturers Cancer Immunotherapy Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Cancer Immunotherapy Drug Product Location Distribution

3.4.2 Players Cancer Immunotherapy Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CANCER IMMUNOTHERAPY DRUG BY GEOGRAPHIC REGION

4.1 World Historic Cancer Immunotherapy Drug Market Size by Geographic Region (2021-2026)

4.1.1 Global Cancer Immunotherapy Drug Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Cancer Immunotherapy Drug Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Cancer Immunotherapy Drug Market Size by Country/Region (2021-2026)

4.2.1 Global Cancer Immunotherapy Drug Annual Sales by Country/Region (2021-2026)

4.2.2 Global Cancer Immunotherapy Drug Annual Revenue by Country/Region

(2021-2026)

4.3 Americas Cancer Immunotherapy Drug Sales Growth

4.4 APAC Cancer Immunotherapy Drug Sales Growth

4.5 Europe Cancer Immunotherapy Drug Sales Growth

4.6 Middle East & Africa Cancer Immunotherapy Drug Sales Growth

5 AMERICAS

5.1 Americas Cancer Immunotherapy Drug Sales by Country

5.1.1 Americas Cancer Immunotherapy Drug Sales by Country (2021-2026)

5.1.2 Americas Cancer Immunotherapy Drug Revenue by Country (2021-2026)

5.2 Americas Cancer Immunotherapy Drug Sales by Type (2021-2026)

5.3 Americas Cancer Immunotherapy Drug Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Cancer Immunotherapy Drug Sales by Region

6.1.1 APAC Cancer Immunotherapy Drug Sales by Region (2021-2026)

6.1.2 APAC Cancer Immunotherapy Drug Revenue by Region (2021-2026)

6.2 APAC Cancer Immunotherapy Drug Sales by Type (2021-2026)

6.3 APAC Cancer Immunotherapy Drug Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Cancer Immunotherapy Drug by Country

7.1.1 Europe Cancer Immunotherapy Drug Sales by Country (2021-2026)

7.1.2 Europe Cancer Immunotherapy Drug Revenue by Country (2021-2026)

7.2 Europe Cancer Immunotherapy Drug Sales by Type (2021-2026)

7.3 Europe Cancer Immunotherapy Drug Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Cancer Immunotherapy Drug by Country

8.1.1 Middle East & Africa Cancer Immunotherapy Drug Sales by Country (2021-2026)

8.1.2 Middle East & Africa Cancer Immunotherapy Drug Revenue by Country (2021-2026)

8.2 Middle East & Africa Cancer Immunotherapy Drug Sales by Type (2021-2026)

8.3 Middle East & Africa Cancer Immunotherapy Drug Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Cancer Immunotherapy Drug

10.3 Manufacturing Process Analysis of Cancer Immunotherapy Drug

10.4 Industry Chain Structure of Cancer Immunotherapy Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Cancer Immunotherapy Drug Distributors

11.3 Cancer Immunotherapy Drug Customer

12 WORLD FORECAST REVIEW FOR CANCER IMMUNOTHERAPY DRUG BY GEOGRAPHIC REGION

12.1 Global Cancer Immunotherapy Drug Market Size Forecast by Region

12.1.1 Global Cancer Immunotherapy Drug Forecast by Region (2027-2032)

12.1.2 Global Cancer Immunotherapy Drug Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Cancer Immunotherapy Drug Forecast by Type (2027-2032)

12.7 Global Cancer Immunotherapy Drug Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Autolus Therapeutics plc

13.1.1 Autolus Therapeutics plc Company Information

13.1.2 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolios and Specifications

13.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Autolus Therapeutics plc Main Business Overview

13.1.5 Autolus Therapeutics plc Latest Developments

13.2 BeiGene

13.2.1 BeiGene Company Information

13.2.2 BeiGene Cancer Immunotherapy Drug Product Portfolios and Specifications

13.2.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 BeiGene Main Business Overview

13.2.5 BeiGene Latest Developments

13.3 bluebird bio, Inc.

13.3.1 bluebird bio, Inc. Company Information

13.3.2 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

13.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and

Gross Margin (2021-2026)

13.3.4 bluebird bio, Inc. Main Business Overview

13.3.5 bluebird bio, Inc. Latest Developments

13.4 Bristol-Myers Squibb

13.4.1 Bristol-Myers Squibb Company Information

13.4.2 Bristol-Myers Squibb Cancer Immunotherapy Drug Product Portfolios and Specifications

13.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Bristol-Myers Squibb Main Business Overview

13.4.5 Bristol-Myers Squibb Latest Developments

13.5 Celgene Corporation

13.5.1 Celgene Corporation Company Information

13.5.2 Celgene Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications

13.5.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Celgene Corporation Main Business Overview

13.5.5 Celgene Corporation Latest Developments

13.6 AstraZeneca plc

13.6.1 AstraZeneca plc Company Information

13.6.2 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolios and Specifications

13.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 AstraZeneca plc Main Business Overview

13.6.5 AstraZeneca plc Latest Developments

13.7 Gilead Sciences, Inc.

13.7.1 Gilead Sciences, Inc. Company Information

13.7.2 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

13.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Gilead Sciences, Inc. Main Business Overview

13.7.5 Gilead Sciences, Inc. Latest Developments

13.8 Incyte Corporation

13.8.1 Incyte Corporation Company Information

13.8.2 Incyte Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications

13.8.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Incyte Corporation Main Business Overview

13.8.5 Incyte Corporation Latest Developments

13.9 Jiangsu Hengrui Medicine

13.9.1 Jiangsu Hengrui Medicine Company Information

13.9.2 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Portfolios and Specifications

13.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Jiangsu Hengrui Medicine Main Business Overview

13.9.5 Jiangsu Hengrui Medicine Latest Developments

13.10 Juno Pharmaceuticals Pty Ltd.

13.10.1 Juno Pharmaceuticals Pty Ltd. Company Information

13.10.2 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolios and Specifications

13.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Juno Pharmaceuticals Pty Ltd. Main Business Overview

13.10.5 Juno Pharmaceuticals Pty Ltd. Latest Developments

13.11 Medimmune, LLC

13.11.1 Medimmune, LLC Company Information

13.11.2 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolios and Specifications

13.11.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Medimmune, LLC Main Business Overview

13.11.5 Medimmune, LLC Latest Developments

13.12 Merck & Co., Inc.

13.12.1 Merck & Co., Inc. Company Information

13.12.2 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

13.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Merck & Co., Inc. Main Business Overview

13.12.5 Merck & Co., Inc. Latest Developments

13.13 Novartis AG

13.13.1 Novartis AG Company Information

13.13.2 Novartis AG Cancer Immunotherapy Drug Product Portfolios and

Specifications

13.13.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Novartis AG Main Business Overview

13.13.5 Novartis AG Latest Developments

13.14 Pfizer, Inc.

13.14.1 Pfizer, Inc. Company Information

13.14.2 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

13.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Pfizer, Inc. Main Business Overview

13.14.5 Pfizer, Inc. Latest Developments

13.15 Roche Holding AG

13.15.1 Roche Holding AG Company Information

13.15.2 Roche Holding AG Cancer Immunotherapy Drug Product Portfolios and Specifications

13.15.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Roche Holding AG Main Business Overview

13.15.5 Roche Holding AG Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Cancer Immunotherapy Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Cancer Immunotherapy Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of PD-1 Inhibitor

Table 4. Major Players of PDL-1 Inhibitor

Table 5. Major Players of T-Cell Stimulant

Table 6. Major Players of CTLA Antibody

Table 7. Global Cancer Immunotherapy Drug Sales by Type (2021-2026) & (K Units)

Table 8. Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026)

Table 9. Global Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2026)

Table 11. Global Cancer Immunotherapy Drug Sale Price by Type (2021-2026) & (US\$/Unit)

Table 12. Global Cancer Immunotherapy Drug Sale by Application (2021-2026) & (K Units)

Table 13. Global Cancer Immunotherapy Drug Sale Market Share by Application (2021-2026)

Table 14. Global Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (\$ million)

Table 15. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2026)

Table 16. Global Cancer Immunotherapy Drug Sale Price by Application (2021-2026) & (US\$/Unit)

Table 17. Global Cancer Immunotherapy Drug Sales by Company (2021-2026) & (K Units)

Table 18. Global Cancer Immunotherapy Drug Sales Market Share by Company (2021-2026)

Table 19. Global Cancer Immunotherapy Drug Revenue by Company (2021-2026) & (\$ millions)

Table 20. Global Cancer Immunotherapy Drug Revenue Market Share by Company (2021-2026)

Table 21. Global Cancer Immunotherapy Drug Sale Price by Company (2021-2026) &

(US\$/Unit)

Table 22. Key Manufacturers Cancer Immunotherapy Drug Producing Area Distribution and Sales Area

Table 23. Players Cancer Immunotherapy Drug Products Offered

Table 24. Cancer Immunotherapy Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Cancer Immunotherapy Drug Sales by Geographic Region (2021-2026) & (K Units)

Table 28. Global Cancer Immunotherapy Drug Sales Market Share Geographic Region (2021-2026)

Table 29. Global Cancer Immunotherapy Drug Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 30. Global Cancer Immunotherapy Drug Revenue Market Share by Geographic Region (2021-2026)

Table 31. Global Cancer Immunotherapy Drug Sales by Country/Region (2021-2026) & (K Units)

Table 32. Global Cancer Immunotherapy Drug Sales Market Share by Country/Region (2021-2026)

Table 33. Global Cancer Immunotherapy Drug Revenue by Country/Region (2021-2026) & (\$ millions)

Table 34. Global Cancer Immunotherapy Drug Revenue Market Share by Country/Region (2021-2026)

Table 35. Americas Cancer Immunotherapy Drug Sales by Country (2021-2026) & (K Units)

Table 36. Americas Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026)

Table 37. Americas Cancer Immunotherapy Drug Revenue by Country (2021-2026) & (\$ millions)

Table 38. Americas Cancer Immunotherapy Drug Sales by Type (2021-2026) & (K Units)

Table 39. Americas Cancer Immunotherapy Drug Sales by Application (2021-2026) & (K Units)

Table 40. APAC Cancer Immunotherapy Drug Sales by Region (2021-2026) & (K Units)

Table 41. APAC Cancer Immunotherapy Drug Sales Market Share by Region (2021-2026)

Table 42. APAC Cancer Immunotherapy Drug Revenue by Region (2021-2026) & (\$ millions)

Table 43. APAC Cancer Immunotherapy Drug Sales by Type (2021-2026) & (K Units)

Table 44. APAC Cancer Immunotherapy Drug Sales by Application (2021-2026) & (K Units)

Table 45. Europe Cancer Immunotherapy Drug Sales by Country (2021-2026) & (K Units)

Table 46. Europe Cancer Immunotherapy Drug Revenue by Country (2021-2026) & (\$ millions)

Table 47. Europe Cancer Immunotherapy Drug Sales by Type (2021-2026) & (K Units)

Table 48. Europe Cancer Immunotherapy Drug Sales by Application (2021-2026) & (K Units)

Table 49. Middle East & Africa Cancer Immunotherapy Drug Sales by Country (2021-2026) & (K Units)

Table 50. Middle East & Africa Cancer Immunotherapy Drug Revenue Market Share by Country (2021-2026)

Table 51. Middle East & Africa Cancer Immunotherapy Drug Sales by Type (2021-2026) & (K Units)

Table 52. Middle East & Africa Cancer Immunotherapy Drug Sales by Application (2021-2026) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Cancer Immunotherapy Drug

Table 54. Key Market Challenges & Risks of Cancer Immunotherapy Drug

Table 55. Key Industry Trends of Cancer Immunotherapy Drug

Table 56. Cancer Immunotherapy Drug Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Cancer Immunotherapy Drug Distributors List

Table 59. Cancer Immunotherapy Drug Customer List

Table 60. Global Cancer Immunotherapy Drug Sales Forecast by Region (2027-2032) & (K Units)

Table 61. Global Cancer Immunotherapy Drug Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 62. Americas Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 63. Americas Cancer Immunotherapy Drug Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 64. APAC Cancer Immunotherapy Drug Sales Forecast by Region (2027-2032) & (K Units)

Table 65. APAC Cancer Immunotherapy Drug Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 66. Europe Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Europe Cancer Immunotherapy Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Middle East & Africa Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 69. Middle East & Africa Cancer Immunotherapy Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Global Cancer Immunotherapy Drug Sales Forecast by Type (2027-2032) & (K Units)

Table 71. Global Cancer Immunotherapy Drug Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 72. Global Cancer Immunotherapy Drug Sales Forecast by Application (2027-2032) & (K Units)

Table 73. Global Cancer Immunotherapy Drug Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 74. Autolus Therapeutics plc Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 75. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 76. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 77. Autolus Therapeutics plc Main Business

Table 78. Autolus Therapeutics plc Latest Developments

Table 79. BeiGene Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 80. BeiGene Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 81. BeiGene Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 82. BeiGene Main Business

Table 83. BeiGene Latest Developments

Table 84. bluebird bio, Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 85. bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 86. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 87. bluebird bio, Inc. Main Business

Table 88. bluebird bio, Inc. Latest Developments

Table 89. Bristol-Myers Squibb Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 90. Bristol-Myers Squibb Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 91. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. Bristol-Myers Squibb Main Business

Table 93. Bristol-Myers Squibb Latest Developments

Table 94. Celgene Corporation Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. Celgene Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 96. Celgene Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. Celgene Corporation Main Business

Table 98. Celgene Corporation Latest Developments

Table 99. AstraZeneca plc Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. AstraZeneca plc Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 101. AstraZeneca plc Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. AstraZeneca plc Main Business

Table 103. AstraZeneca plc Latest Developments

Table 104. Gilead Sciences, Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 106. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 107. Gilead Sciences, Inc. Main Business

Table 108. Gilead Sciences, Inc. Latest Developments

Table 109. Incyte Corporation Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. Incyte Corporation Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 111. Incyte Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. Incyte Corporation Main Business

Table 113. Incyte Corporation Latest Developments

Table 114. Jiangsu Hengrui Medicine Basic Information, Cancer Immunotherapy Drug

Manufacturing Base, Sales Area and Its Competitors

Table 115. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 116. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. Jiangsu Hengrui Medicine Main Business

Table 118. Jiangsu Hengrui Medicine Latest Developments

Table 119. Juno Pharmaceuticals Pty Ltd. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 121. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Juno Pharmaceuticals Pty Ltd. Main Business

Table 123. Juno Pharmaceuticals Pty Ltd. Latest Developments

Table 124. Medimmune, LLC Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 125. Medimmune, LLC Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 126. Medimmune, LLC Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Medimmune, LLC Main Business

Table 128. Medimmune, LLC Latest Developments

Table 129. Merck & Co., Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 130. Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 131. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. Merck & Co., Inc. Main Business

Table 133. Merck & Co., Inc. Latest Developments

Table 134. Novartis AG Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 135. Novartis AG Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 136. Novartis AG Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 137. Novartis AG Main Business

Table 138. Novartis AG Latest Developments

Table 139. Pfizer, Inc. Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 140. Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 141. Pfizer, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 142. Pfizer, Inc. Main Business

Table 143. Pfizer, Inc. Latest Developments

Table 144. Roche Holding AG Basic Information, Cancer Immunotherapy Drug Manufacturing Base, Sales Area and Its Competitors

Table 145. Roche Holding AG Cancer Immunotherapy Drug Product Portfolios and Specifications

Table 146. Roche Holding AG Cancer Immunotherapy Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 147. Roche Holding AG Main Business

Table 148. Roche Holding AG Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Cancer Immunotherapy Drug
- Figure 2. Cancer Immunotherapy Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Cancer Immunotherapy Drug Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Cancer Immunotherapy Drug Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Cancer Immunotherapy Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Cancer Immunotherapy Drug Sales Market Share by Country/Region (2025)
- Figure 10. Cancer Immunotherapy Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of PD-1 Inhibitor
- Figure 12. Product Picture of PDL-1 Inhibitor
- Figure 13. Product Picture of T-Cell Stimulant
- Figure 14. Product Picture of CTLA Antibody
- Figure 15. Global Cancer Immunotherapy Drug Sales Market Share by Type in 2026
- Figure 16. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2026)
- Figure 17. Cancer Immunotherapy Drug Consumed in Hospital
- Figure 18. Global Cancer Immunotherapy Drug Market: Hospital (2021-2026) & (K Units)
- Figure 19. Cancer Immunotherapy Drug Consumed in Clinic
- Figure 20. Global Cancer Immunotherapy Drug Market: Clinic (2021-2026) & (K Units)
- Figure 21. Cancer Immunotherapy Drug Consumed in Others
- Figure 22. Global Cancer Immunotherapy Drug Market: Others (2021-2026) & (K Units)
- Figure 23. Global Cancer Immunotherapy Drug Sale Market Share by Application (2025)
- Figure 24. Global Cancer Immunotherapy Drug Revenue Market Share by Application in 2026
- Figure 25. Cancer Immunotherapy Drug Sales by Company in 2026 (K Units)
- Figure 26. Global Cancer Immunotherapy Drug Sales Market Share by Company in 2026
- Figure 27. Cancer Immunotherapy Drug Revenue by Company in 2026 (\$ millions)

Figure 28. Global Cancer Immunotherapy Drug Revenue Market Share by Company in 2026

Figure 29. Global Cancer Immunotherapy Drug Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Cancer Immunotherapy Drug Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Cancer Immunotherapy Drug Sales 2021-2026 (K Units)

Figure 32. Americas Cancer Immunotherapy Drug Revenue 2021-2026 (\$ millions)

Figure 33. APAC Cancer Immunotherapy Drug Sales 2021-2026 (K Units)

Figure 34. APAC Cancer Immunotherapy Drug Revenue 2021-2026 (\$ millions)

Figure 35. Europe Cancer Immunotherapy Drug Sales 2021-2026 (K Units)

Figure 36. Europe Cancer Immunotherapy Drug Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Cancer Immunotherapy Drug Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Cancer Immunotherapy Drug Revenue 2021-2026 (\$ millions)

Figure 39. Americas Cancer Immunotherapy Drug Sales Market Share by Country in 2026

Figure 40. Americas Cancer Immunotherapy Drug Revenue Market Share by Country (2021-2026)

Figure 41. Americas Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026)

Figure 42. Americas Cancer Immunotherapy Drug Sales Market Share by Application (2021-2026)

Figure 43. United States Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Cancer Immunotherapy Drug Sales Market Share by Region in 2026

Figure 48. APAC Cancer Immunotherapy Drug Revenue Market Share by Region (2021-2026)

Figure 49. APAC Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026)

Figure 50. APAC Cancer Immunotherapy Drug Sales Market Share by Application (2021-2026)

Figure 51. China Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Cancer Immunotherapy Drug Sales Market Share by Country in 2026

Figure 59. Europe Cancer Immunotherapy Drug Revenue Market Share by Country (2021-2026)

Figure 60. Europe Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026)

Figure 61. Europe Cancer Immunotherapy Drug Sales Market Share by Application (2021-2026)

Figure 62. Germany Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 63. France Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 64. UK Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 65. Italy Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 66. Russia Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 67. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Application (2021-2026)

Figure 70. Egypt Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 71. South Africa Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 72. Israel Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 73. Turkey Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 74. GCC Countries Cancer Immunotherapy Drug Revenue Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Cancer Immunotherapy Drug in 2026

Figure 76. Manufacturing Process Analysis of Cancer Immunotherapy Drug

Figure 77. Industry Chain Structure of Cancer Immunotherapy Drug

Figure 78. Channels of Distribution

Figure 79. Global Cancer Immunotherapy Drug Sales Market Forecast by Region (2027-2032)

Figure 80. Global Cancer Immunotherapy Drug Revenue Market Share Forecast by Region (2027-2032)

Figure 81. Global Cancer Immunotherapy Drug Sales Market Share Forecast by Type (2027-2032)

Figure 82. Global Cancer Immunotherapy Drug Revenue Market Share Forecast by Type (2027-2032)

Figure 83. Global Cancer Immunotherapy Drug Sales Market Share Forecast by Application (2027-2032)

Figure 84. Global Cancer Immunotherapy Drug Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Cancer Immunotherapy Drug Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G3D794ED5B75EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3D794ED5B75EN.html>